Skip to main content
. 2024 Jan 1;59(1):31–37. doi: 10.5152/TurkArchPediatr.2024.23147

Table 1.

Comparison of Clinical and Laboratory Characteristics in Patients With Complications and Without Complications

Patients With Complication
(n = 26)
Patients Without Complication
(n = 58)
P
Age (years) 14.9 ± 2.5 14.1 ± 2.4 .063a
Sex (M/F) 15/13 28/27 .822b
BMI SDS −0.35 ± 1.2 0 ± 1.2 .264a
Diabetes duration, years 7.4 ± 3.6 5.6 ± 3.1 .037 c
Age at diabetes onset, years 7.5 ± 3.2 9 ± 3.5 .065a
Tanner puberty staging 4.1 ± 1.2 3.8 ± 1.3 .307 a
Insulin dosage, U/kg/day 1.07 ± 0.3 1.03 ± 0.2 .332a
HbA1c, % 8.34 ± 1.3 8.47 ± 1.1 .566a
Mean HbA1c, % (last 24 months) 8.55 ± 1.5 8.33 ± 1.6 .786a
Total cholesterol mg/dL 169 ± 35 163 ± 33 .052c
LDL mg/dL 87.1 ± 33 83.5 ± 27 .558c
HDL mg/dL 64.2 ± 17 58 ± 12 .137a
Triglycerides mg/dL 91 ± 43 111 ± 57 .066c
Non-HDL mg/dL 87.1 ± 33 87.1 ± 33 .824c
Uric acid mg/dL 3.05 ± 1.06 3.48 ± 1.12 .093a
Creatinine mg/dL 0.7 ± 0.16 0.72 ± 0.11 .667a
Urine microalbumin–creatinine mg/g 12.3 ± 8.1 8.7 ± 1.6 <.001 c
eGFR, mL/min/1.73 m² 133 ± 33 126 ± 21 .831c
Hypertension 5/28 3/56 .108b
Dyslipidemia 3/28 5/56 .997b
Serum AGEs (AU/mg×103) 49.6 ± 32.5 41.7 ± 16.4 .351c
 a) Nephropathy (n = 13) 64.8 ± 43.6 41.7 ± 16.4 .032 d .023 e
 b) Peripheral neuropathy (n = 3 ) 39.6 ± 13.6 .973e
 c) Retinopathy (n = 3) 28.7 ± 18.8 .383e
 d) Optic neuropathy
(n = 14)
38.6 ± 10.6 .631e

BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SDS, standard deviation score.

aStudent’s t-test.

bchi-Ssquare test.

cMann–Whitney U-test,

dKruskal–Wallis test.

eDunn’s test.